Recent Updates
Recently added Catalysts
EXEL Positive Sentiment

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Exelixis, Inc. announced that the U.S. Court of Appeals for the Federal Circuit has upheld a significant part of a previous judgment in its favor against MSN Laboratories. This ruling affirms the validity of three patents that are crucial to Exelixis' interests in the ongoing litigation. The decision is seen as a positive development for the company.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appellate court affirmed Exelixis' favorable judgment.
  • Three patents covering important aspects were upheld.
  • Strengthens Exelixis' position in ongoing litigation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+40%
120-day peak, hindsight
Typical move
2.5%
average across 7 past catalysts
Lead asset
Zanzalintinib
Phase 2 · Head and Neck Squamous Cell Carcinoma

Full Press Release Details

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis’ favor. The appellate court upheld the District Court's decision that three patents covering

Frequently Asked Questions

What was the outcome of the Exelixis vs. MSN case?

The U.S. Court of Appeals upheld a key judgment in favor of Exelixis.

How many patents were affirmed in the ruling?

Three patents covering important aspects were upheld by the appellate court.

What court made the ruling on the Exelixis case?

The ruling was made by the U.S. Court of Appeals for the Federal Circuit.

What is the significance of this ruling for Exelixis?

The ruling strengthens Exelixis' position in its ongoing litigation against MSN Laboratories.

ShareAdd on Google
Tags: EXEL Viatris Investor Conferences Healthcare Exelixis MSN Laboratories patent appeal litigation U.S. Court of Appeals
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$1384M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ZanzalintinibPhase 2
Head and Neck Squamous Cell Carcinoma →

Catalyst track record

+40%
best trade around EXEL's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for EXEL.

See every catalyst's timing & PoA →